[1]
Sales, P.M.; Souza, P.M.; Simeoni, L.A.; Magalhães, P.O.; Silveira, D. α-Amylase inhibitors: a review of raw material and isolated compounds from plant source. J. Pharm. Pharmaceut. Sci., 2012, 15, 141-183.
[2]
Funke, I.; Melzig, M.F. Traditionally used plants in diabetes therapy: phytotherapeutics as inhibitors of alpha-amylase activity. Rev. Bras. Farmacogn., 2006, 16, 1-5.
[3]
Inzucchi, S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA, 2002, 287, 360-372.
[4]
Göke, B.; Herrmann-Rinke, C. The evolving role of α‐glucosidase inhibitors. Diabetes Metabolism . Rev., 1998, 14, S31-S38.
[5]
He, L. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev., 1998, 6, 132-145.
[6]
Whitcomb, D.C.; Lowe, M.E. Human pancreatic digestive enzymes. Dig. Dis. Sci., 2007, 52, 1-17.
[7]
Kandra, L. α-Amylases of medical and industrial importance. J. Mol. Struct. Theochem, 2003, 666, 487-498.
[8]
Van de Laar, F.A.; Lucassen, P.L.; Akkermans, R.P.; Van de Lisdonk, E.H.; Rutten, G.E.; Van Weel, C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Cochrane Review). The Cochrane Library., 2005.
[9]
Cheng, A.Y.; Fantus, I.G. Oral antihyperglycemic therapy for type 2 diabetes mellitus. Canadian . Med. Assoc. J., 2005, 172, 213-226.
[10]
Tarling, C.A.; Woods, K.; Zhang, R.; Brastianos, H.C.; Brayer, G.D.; Andersen, R.J.; Withers, S.G. The search for novel human pancreatic α-amylase inhibitors: high-throughput screening of terrestrial and marine natural product extracts. ChemBioChem, 2008, 9, 433-438.
[11]
Hoult, J.; Paya, M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen. Pharmacol.: Vascul. Syst., 1996, 27, 713-722.
[12]
Sashidhara, K.V.; Kumar, A.; Kumar, M.; Sarkar, J.; Sinha, S. Synthesis and in vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer agents. Bioorg. Med. Chem. Lett., 2010, 20, 7205-7211.
[13]
Kidane, A.G.; Salacinski, H.; Tiwari, A.; Bruckdorfer, K.R.; Seifalian, A.M. Anticoagulant and antiplatelet agents: their clinical and device application (s) together with usages to engineer surfaces. Biomacromolecules, 2004, 5, 798-813.
[14]
Ma, T.; Liu, L.; Xue, H.; Li, L.; Han, C.; Wang, L.; Chen, Z.; Liu, G. Chemical library and structure-activity relationships of 11-demethyl-12-oxo calanolide A analogues as anti-HIV-1 agents. J. Med. Chem., 2008, 51, 1432-1446.
[15]
Kontogiorgis, C.A.; Hadjipavlou-Litina, D.J. Synthesis and biological evaluation of novel coumarin derivatives with a 7-azomethine linkage. Bioorg. Med. Chem. Lett., 2004, 14, 611-614.
[16]
Khan, K.M.; Saify, Z.S.; Khan, M.Z. Zia-Ullah; Iqbal, A.; Choudhary, M.I.; Atta-ur-Rahman; Perveen, S.; Chohan, Z.H.; Supuran, C.T. Synthesis of coumarin derivatives with cytotoxic, antibacterial and antifungal activity. J. Enzyme Inhib. Med. Chem., 2004, 19, 373-379.
[17]
Salar, U.; Khan, K.M.; Jabeen, A.; Faheem, A.; Fakhri, M.I.; Saad, S.M.; Perveen, S.; Taha, M.; Hammed, A. Coumarin sulfonates: As potential leads for ROS inhibition. Bioorg. Chem., 2016, 69, 34-47.
[18]
Kempen, I.; Papapostolou, D.; Thierry, N.; Pochet, L.; Counerotte, S.; Masereel, B.; Foidart, J-M.; Reboud-Ravaux, M.; Noël, A.; Pirotte, B. 3-Bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzo-pyran-3-carboxylate inhibits cancer cell invasion in vitro and tumour growth in vivo. British . J. Cancer, 2003, 88, 1111-1118.
[19]
Sashidhara, K.V.; Rosaiah, J.N.; Kumar, A.; Bhatia, G.; Khanna, A. Synthesis of novel benzocoumarin derivatives as lipid lowering agents. Bioorg. Med. Chem. Lett., 2010, 20, 3065-3069.
[20]
Kostova, I. Synthetic and natural coumarins as cytotoxic agents. Curr. Med. Chem. Anticancer Agents, 2005, 5, 29-46.
[21]
Musa, M.A.; Cooperwood, J.S.; Khan, M.O.F. A review of coumarin derivatives in pharmacotherapy of breast cancer. Curr. Med. Chem., 2008, 15, 2664-2679.
[22]
Peng, X-M.; L.V., Damu G.; Zhou, H. Current developments of coumarin compounds in medicinal chemistry. Curr. Pharm. Des., 2013, 19, 3884-3930.
[23]
Medina, F.G.; Marrero, J.G.; Macías-Alonso, M.; González, M.C.; Córdova-Guerrero, I.; García, A.G.T.; Osegueda-Robles, S. Coumarin heterocyclic derivatives: Chemical synthesis and biological activity. Nat. Prod. Rep., 2015, 32, 1472-1507.
[24]
Kashyap, S.J.; Garg, V.K.; Sharma, P.K.; Kumar, N.; Dudhe, R.; Gupta, J.K. Thiazoles: having diverse biological activities. Med. Chem. Res., 2012, 21, 2123-2132.
[25]
Siddiqui, N.; Arshad, M.F.; Ahsan, W.; Alam, M.S. Thiazoles: a valuable insight into the recent advances and biological activities. Int. J. Pharm. Sci. Drug Res., 2009, 1, 136-143.
[26]
(a)Arshad, T.; Khan, K.M.; Rasool, N.; Salar, U.; Hussain, S.; Asghar, H.; Ashraf, M.; Wadood, A.; Riaz, M.; Perveen, S.; Taha, M.; Ismail, N.H. 5-Bromo-2-aryl benzimidazole derivatives as non-cytotoxic potential dual inhibitors of α-glucosidase and urease enzymes. Bioorg. Chem., 2017, 72, 21-31.
(b)Khan, K.M.; Qurban, S.; Salar, U.; Taha, M.; Hussain, S.; Perveen, S.; Hameed, A.; Ismail, N.H.; Riaz, M.; Wadood, A. Synthesis, in vitro α-glucosidase inhibitory activity and molecular docking studies of new thiazole derivatives. Bioorg. Chem., 2016, 68, 245-258.
(c)Arshad, T.; Khan, K.M.; Rasool, N.; Salar, U.; Hussain, S.; Tahir, T.; Ashraf, M.; Wadood, A.; Riaz, M.; Perveen, S.; Taha, M.; Ismail, N.H. Syntheses, in vitro evaluation and molecular docking studies of 5-bromo-2-aryl benzimidazoles as α-glucosidase inhibitors. Med. Chem. Res., 2016, 25, 2058-2069.
(d)Javaid, K.; Saad, S.M.; Rasheed, S.; Moin, S.T.; Syed, N.; Fatima, I.; Salar, U.; Khan, K.M.; Perveen, S.; Choudhary, M.I. 2-Arylquinazolin-4(3H)-ones: A new class of α-glucosidase inhibitors. Bioorg. Med. Chem., 2015, 23, 7417-7421.
(e)Bano, B.; Abbasi, S.; Khan, J.A.J.; Hussain, S.; Rasheed, S.; Perveen, S.; Khan, K.M.; Choudhary, M.I. Antiglycation activity of quinoline derivatives- A new therapeutic class for the management of type 2 diabetes complications. Med. Chem., 2015, 11, 60-68.
(f)Abbasi, S.; Mirza, S.; Rasheed, S.; Hussain, S.; Khan, J.A.J.; Khan, K.M.; Perveen, S.; Choudhary, M.I. Benzothiazole derivatives: Novel inhibitors of methylglyoxal mediated glycation of protein in vitro. Med. Chem., 2014, 10, 824-835.
(g)Khan, K.M.; Khan, M.; Ambreen, N.; Taha, M.; Rahim, F.; Rasheed, S.; Saied, S.; Safi, H.; Perveen, S.; Choudhary, M.I. Oxindole derivatives: Synthesis and antiglycation activity. Med. Chem., 2013, 9, 681-688.
[27]
Salar, U.; Taha, M.; Khan, K.M.; Ismail, N.H.; Imran, S.; Perveen, S.; Gul, S.; Wadood, A. Syntheses of new 3-thiazolyl coumarin derivatives, in vitro α-glucosidase inhibitory activity, and molecular modeling studies. Eur. J. Med. Chem., 2016, 122, 196-204.
[28]
Asmat, U.; Abad, K.; Ismail, K. Diabetes mellitus and oxidative stress—a concise review. SPJ, 2016, 24, 547-553.
[29]
Kwon, Y-I.; Apostolidis, E.; Shetty, K. In vitro studies of eggplant (Solanum melongena) phenolics as inhibitors of key enzymes relevant for type 2 diabetes and hypertension. Bioresour. Technol., 2008, 99, 2981-2988.
[30]
Loh, S.P.; Hadira, O. In vitro inhibitory potential of selected Malaysian plants against key enzymes involved in hyperglycemia and hypertension. Malays. J. Nutr., 2011, 17, 77-86.
[31]
Tayyaba, N.; Muhammad, T.; Syahrul, I.; Sridevi, C.H.; Rahim, F.; Selvaraj, M.; Irshad, M. Synthesis of alpha amylase inhibitors based on privileged indole scaffold. Bioorg. Chem., 2017, 72, 248-255.
[32]
Suthakaran, R.; Somasekhar, G.; Sridevi, C.; Marikannan, M.; Suganthi, K.; Nagarajan, G. Synthesis, antiinflammatory, antioxi-dant and antibacterial activities of 7-methoxy benzofuran pyra-zoline derivatives. Asian J. Chem., 2007, 19, 3353-3362.
[33]
Sridevi, C.H.; Balaji, K.; Naidu, A.; Sudhakaran, R. Antioxidant, anti-inflammatory and histaminic activities of some phenyl pyrazolo benzothiazolo quinoxaline derivatives. Int. J. Chem. Sci., 2009, 7, 1117-1126.
[34]
Chigurupati, S.; Selvaraj, M.; Mani, V.; Selvarajan, K.K.; Mohammad, J.I.; Kaveti, B.; Bera, H.; Palanimuthu, V.R.; Teh, L.K.; Salleh, M.Z. Identification of novel acetylcholinesterase inhibitors: Indolopyrazoline derivatives and molecular docking studies. Bioorg. Chem., 2016, 67, 9-17.
[35]
Leach, A.R.; Shoichet, B.K.; Peishoff, C.E. Prediction of protein-ligand interactions. Docking and scoring: Successes and gaps. J. Med. Chem., 2006, 49, 5851-5855.